Mithra Pharmaceuticals S.A.
ISIN: BE0974283153 | Ticker: MITRA | LEI: 5493002FDD273HTEKK14
Country: Belgium
We are committed to providing women new choices improving their daily life
For over twenty years, Mithra has dedicated its researches so as to redefine women’s health by bringing innovative products in the fields of contraception and menopause.
Today, Mithra counts two complementary platforms: its portfolio of innovative products based on Estetrol (E4) and its portfolio of Complex Therapeutics. The whole supported by the Mithra CDMO, a technological platform offering a wide range of services going from pharmaceutical development to commercial manufacturing.
Since the launch of the first generic contraceptive pill in Belgium, Mithra always focused on innovation for women.
After years of research and development, our pipeline today includes late-stage development products, potential blockbusters and complex therapeutics in the fields of contraception and menopause. These projects are powered by our Mithra CDMO, our unique R&D and manufacturing platform.
1999
Served areaWorldwide
Headcount350
HeadquartersRue Saint-George 5, 4000 Rocourt, Liège – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 521,985,000.00 | 421,918,000.00 | 442,414,000.00 |
| Noncurrent Assets | N/A | 283,509,000.00 | 322,528,000.00 | 296,552,000.00 |
| Property Plant And Equipment | N/A | 29,921,000.00 | 38,354,000.00 | 40,717,000.00 |
| Goodwill | N/A | 5,233,000.00 | 5,233,000.00 | 5,233,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 89,005,000.00 | 104,954,000.00 | 134,905,000.00 |
| Deferred Tax Assets | N/A | 50,905,000.00 | 63,456,000.00 | 16,354,000.00 |
| Noncurrent Derivative Financial Assets | N/A | 6,184,000.00 | 0.00 | N/A |
| Other Noncurrent Assets | N/A | 14,401,000.00 | 9,263,000.00 | 9,544,000.00 |
| Current Assets | N/A | 238,475,000.00 | 99,389,000.00 | 145,863,000.00 |
| Inventories | N/A | 35,382,000.00 | 43,852,000.00 | 50,312,000.00 |
| Trade And Other Current Receivables | N/A | 10,052,000.00 | 10,044,000.00 | 22,277,000.00 |
| Cash and cash equivalents | 49,720,000.00 | 138,675,000.00 | 32,872,000.00 | 28,285,000.00 |
| Current Derivative Financial Assets | N/A | 2,881,000.00 | 100,000.00 | 0.00 |
| Shortterm Deposits Not Classified As Cash Equivalents | N/A | 14,000.00 | 0.00 | N/A |
| Equity And Liabilities | N/A | 521,985,000.00 | 421,918,000.00 | 442,414,000.00 |
| Equity | 163,298,000.00 | 157,737,000.00 | 33,840,000.00 | 33,687,000.00 |
| Issued Capital | N/A | 31,271,000.00 | 32,250,000.00 | 41,228,000.00 |
| Retained Earnings | N/A | -219,759,000.00 | -336,633,000.00 | -396,254,000.00 |
| Other Reserves | N/A | 13,690,000.00 | -2,545,000.00 | -19,934,000.00 |
| Additional Paidin Capital | N/A | 332,535,000.00 | 340,769,000.00 | 408,647,000.00 |
| Noncurrent Liabilities | N/A | 293,500,000.00 | 292,285,000.00 | 278,298,000.00 |
| Noncurrent Provisions | N/A | 266,000.00 | 266,000.00 | 266,000.00 |
| Noncurrent Contract Liabilities | N/A | 3,706,000.00 | 0.00 | N/A |
| Noncurrent Government Grants | N/A | 15,195,000.00 | 12,769,000.00 | 8,127,000.00 |
| Deferred Tax Liabilities | N/A | 4,363,000.00 | 6,089,000.00 | 4,420,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 101,180,000.00 | 102,675,000.00 | 74,210,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 0.00 | 2,897,000.00 | 15,261,000.00 |
| Longterm Borrowings | N/A | 111,898,000.00 | 113,608,000.00 | 127,052,000.00 |
| Current Liabilities | N/A | 70,747,000.00 | 95,793,000.00 | 130,431,000.00 |
| Trade And Other Current Payables | N/A | 27,272,000.00 | 23,331,000.00 | 58,082,000.00 |
| Current Government Grants | N/A | 1,259,000.00 | 1,617,000.00 | 1,417,000.00 |
| Other Current Financial Liabilities | N/A | 23,424,000.00 | 15,829,000.00 | 15,959,000.00 |
| Current Derivative Financial Liabilities | N/A | 0.00 | 1,886,000.00 | 2,561,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 9,030,000.00 | 22,668,000.00 | 66,997,000.00 |
| Other Income | 6,574,000.00 | 4,809,000.00 | 7,196,000.00 |
| Profit Loss From Operating Activities | -83,678,000.00 | -87,875,000.00 | -26,245,000.00 |
| Finance Income | 1,782,000.00 | 2,838,000.00 | 9,852,000.00 |
| Finance Costs | 5,987,000.00 | 13,116,000.00 | 23,422,000.00 |
| Profit Loss Before Tax | -110,922,000.00 | -123,769,000.00 | -11,480,000.00 |
| Income Tax Expense Continuing Operations | -18,835,000.00 | -6,895,000.00 | 48,139,000.00 |
| Profit (loss) | -92,086,000.00 | -116,875,000.00 | -59,620,000.00 |
| Profit Loss Attributable To Owners Of Parent | N/A | -116,875,000.00 | -59,620,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | N/A | 0.00 | 0.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -92,086,000.00 | -116,875,000.00 | -59,620,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -19,105,000.00 | -8,470,000.00 | -6,873,000.00 |
| Adjustments For Sharebased Payments | N/A | 7,267,000.00 | 1,065,000.00 | 1,983,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -80,025,000.00 | -76,788,000.00 | -56,819,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 23,000.00 | 0.00 | 169,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 10,645,000.00 | 11,483,000.00 | 6,356,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 5,585,000.00 | 9,699,000.00 | 19,302,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -16,207,000.00 | -54,682,000.00 | -25,490,000.00 |
| Proceeds From Issuing Shares | N/A | 65,731,000.00 | 9,213,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,475,000.00 | 7,193,000.00 | 6,663,000.00 |
| Proceeds From Government Grants Classified As Financing Activities | N/A | 5,835,000.00 | 41,000.00 | 154,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 3,503,000.00 | 9,364,000.00 | 9,862,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 185,187,000.00 | 25,646,000.00 | 77,869,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 21,000.00 | -147,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 88,954,000.00 | -105,824,000.00 | -4,440,000.00 |
| Cash and cash equivalents | 49,720,000.00 | 138,675,000.00 | 32,872,000.00 | 28,285,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 17.01.23 | NOSHAQ SA | Board | Other | EUR 617,814.92 |
| 17.11.22 | NOSHAQ SA | Board | Other | EUR 1,052,701.40 |
| 18.07.22 | NOSHAQ SA | Board | Other | EUR 1,006,250.00 |
| 13.05.22 | NOSHAQ SA | Board | Other | EUR 1,239,062.50 |
| 13.04.22 | Gordenne Valérie | Other | Sell | EUR 87,380.00 |
| 29.03.22 | Fornieri Francesco | Board | Sell | EUR 1,312,000.00 |
| 25.03.22 | Fornieri Francesco | Board | Sell | EUR 486,530.57 |
| 24.03.22 | Fornieri Francesco | Board | Sell | EUR 219,536.19 |
| 24.03.22 | Fornieri Francesco | Board | Sell | EUR 39,452.00 |
| 23.03.22 | Fornieri Francesco | Board | Sell | EUR 178,230.75 |
BE0974283153
LEI5493002FDD273HTEKK14
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.